louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05334849: Prospectively Predict the Immunotherapy Response of Gastric Cancer Based on Circulating Exosomal LncRNA-GC1 Biopsy
Official title: Prospectively Predict the Efficacy of Precise Immunotherapy Response of Gastric Cancer Based on Circulating Exosomal LncRNA-GC1 Biopsy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Advanced Gastric Carcinoma
Immunotherapy
Keywords: Circulating exosomal lncRNA-GC1
Advanced Gastric Carcinoma
Immunotherapy response
Lead sponsor: Chinese PLA General Hospital
Sponsor class: OTHER
First posted: 2022-04-19
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All patients in this study were enrolled by the Department of General Surgery, Chinese PLA General Hospital for conventional therapy or clinical trials

Brief summary: To vertify the function of circulating exosomal lncRNA-GC1 on predicting and monitoring immunotherapeutic outcomes of GC

Detailed description: The investigator's previous work identified circulating exosomal lncRNA-GC1 as a GC-specific tumor burden marker and this novel biomarker showed promising efficiency in monitoring disease progression during treatment.

Hence in this stuty, the investigator plan to recruit a prospective cohort to support the conclusions, and provide biomarkers to realize predicting and monitoring immunotherapeutic outcomes of GC.

Eligibility criteria: Inclusion Criteria:

* Having signed informed consent
* Age≥ 18 years old
* Histologically confirmed gastric adenocarcinoma
* Unresectable recurrent or metastatic disease
* Measurable disease according to the RECIST criteria
* Life expectancy of ≥3 month
* No prior chemotherapy of the study more than 4 weeks
* Immunotherapy regimens were included in the treatment

Exclusion Criteria:

* Other previous malignancy within 5 year
* Surgery (excluding diagnostic biopsy) within 4 weeks prior to study
* Pregnancy or lactation period
* Legal incapacity

Primary outcomes:
measure: Levels of circulating exosomal lncRNA-GC1
timeFrame: Circulating exosomal lncRNA-GC1 was detected, analysis and reported at the baseline
measure: Levels of circulating exosomal lncRNA-GC1
timeFrame: Circulating exosomal lncRNA-GC1 was detected, analysis and reported through study completion, average 1 year
Secondary outcomes:
measure: Survival outcomes of circulating exosomal lncRNA-GC1
timeFrame: up to 3 years
Other outcomes:
Locations:
city: Beijing
country: China
facility: Chinese PLA General Hospital
state: Beijing
Study officials:
References:
Clinical trial NCT02590549: MyoRing Implantation With Corneal Collagen Crosslinking for Keratoconus
Official title: Complete Corneal Ring (MyoRing) Implantation Combined With Corneal Collagen Crosslinking for Keratoconus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Keratoconus
Keywords: Keratoconus
riboflavin
corneal collagen crosslinking
intrasromal ring
Lead sponsor: Ufa Eye Research Institute
Sponsor class: OTHER
First posted: 2015-10-29
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A complete intrastromal ring, MyoRing (Dioptex, GmbH, Linz, Austria), suggested by Albert Daxer in 2007, is a relatively new technique that has been demonstrated to treat keratoconus safely and effectively.Corneal collagen crosslinking (CXL), introduced by Wollensak et al. in 2003, has become a standard treatment for progressive keratoconus to slow or possibly stop progression of disease.

The formation of the stromal pocket during MyoRing implantation offers the opportunity for simultaneous introduction of riboflavin 0.1% into the pocket followed by UVA irradiation to provide combined treatment in patients with progressive keratoconus.


Eligibility criteria: Inclusion Criteria:

* \>18 years old
* a diagnosis of keratoconus, intolerance for contact lenses or glasses
* a documented progression of disease. This progression was defined by the following changes over 1 year: an increase of the steepest K by 1.0 diopter (D) or more in manifest cylinder, or an increase of 0.5 D or more in manifest spherical equivalent (SE) refraction by repeated keratotopography ODP-scan ARK-1000 (Nidek, Japan)

Exclusion Criteria:

* minimal pachymetry of less than 380 μm,
* a history of previous ocular pathology or ocular surgery;
* pregnancy or breastfeeding;
* corneal scarring.

Primary outcomes:
measure: K max
timeFrame: 2 years
Secondary outcomes:
measure: Visual acuity as assessed by Decimal system
timeFrame: 2 years
Other outcomes:
Locations:
Study officials:
affiliation: Ufa Eye Research Institute
name: Mukharram Bikbov, Professor
role: STUDY_CHAIR
References:
citation: Jadidi K, Mosavi SA, Nejat F, Naderi M, Janani L, Serahati S. Intrastromal corneal ring segment implantation (keraring 355 degrees ) in patients with central keratoconus: 6-month follow-up. J Ophthalmol. 2015;2015:916385. doi: 10.1155/2015/916385. Epub 2015 Jan 5.
Clinical trial NCT02515149: Impact on Linkage to HIV Care With Point of Care CD4 Testing and Home-based HIV Testing in Kenya
Official title: Randomized Controlled Trial to Assess Accuracy, Feasibility, Acceptability, Cost Effectiveness and Impact of Point of Care CD4 Testing on HIV Diagnosis, Linkage to Care and Time to Antiretroviral Therapy Initiation Among HIV Infected Patients in Rural Western Kenya
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: HIV
Keywords: linkage to care
point of care diagnostics
point of care CD4
HIV care cascade
Kenya
Lead sponsor: Centers for Disease Control and Prevention
Sponsor class: FED
Collaborators: name: Kenya Medical Research Institute
name: United States President's Emergency Plan for AIDS Relief
First posted: 2015-08-04
Enrollment: 770
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Randomised Controlled Trial to Assess Accuracy, Feasibility, Acceptability, Cost Effectiveness and Impact of Point of Care CD4 Testing on HIV Diagnosis, Linkage to Care and Time to Antiretroviral Therapy Initiation among HIV Infected Patients in Rural Western Kenya.


Eligibility criteria: Inclusion Criteria: adults living in the study catchment area (Gem Village, Nyanza province Western Kenya) served by one of 23 HIV clinics and 3 referral labs

* Not having received HIV care in prior 6 months if known HIV+

Exclusion Criteria:

* current HIV care or HIV care within last six months

Primary outcomes:
measure: Linkage to HIV care
timeFrame: Within six months from date of study enrollment
measure: ART initiation
timeFrame: Within six months from date of study enrollment
Secondary outcomes:
Other outcomes:
Locations:
city: Kisumu
country: Kenya
facility: CDC - KEMRI Field Research Station
state: Nyanza
Study officials:
References:
citation: Desai MA, Okal DO, Rose CE, Ndivo R, Oyaro B, Otieno FO, Williams T, Chen RT, Zeh C, Samandari T. Effect of point-of-care CD4 cell count results on linkage to care and antiretroviral initiation during a home-based HIV testing campaign: a non-blinded, cluster-randomised trial. Lancet HIV. 2017 Sep;4(9):e393-e401. doi: 10.1016/S2352-3018(17)30091-7. Epub 2017 May 31.
Clinical trial NCT00268749: Glycine Treatment of Prodromal Symptoms
Official title: Glycine Treatment of Prodromal Symptoms
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Schizophrenia
Lead sponsor: Yale University
Sponsor class: OTHER
Collaborators: name: Stanley Medical Research Institute
First posted: 2005-12-22
Enrollment: 10
Sex: ALL
Minimum age (years): 14
Maximum age (years): 35
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is an open label trial of the NMDA agonist glycine used alone for symptoms that appear to be prodromal for schizophrenia in adolescents and young adults.


Eligibility criteria: Inclusion Criteria:

* age 14-35
* meets SIPS criteria for psychosis prodrome

Exclusion Criteria:

* current antipsychotic medication
* more than 4 weeks of antipsychotic medication lifetime

Primary outcomes:
measure: Scale Of Prodromal Symptoms total score
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Yale University
name: Scott W Woods, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Woods SW, Walsh BC, Hawkins KA, Miller TJ, Saksa JR, D'Souza DC, Pearlson GD, Javitt DC, McGlashan TH, Krystal JH. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. Eur Neuropsychopharmacol. 2013 Aug;23(8):931-40. doi: 10.1016/j.euroneuro.2012.09.008. Epub 2012 Oct 22.
Clinical trial NCT00764049: Single Pass Albumin Dialysis in Patients With Cirrhosis
Official title: Prospective Pilot Study Assessing Safety and Efficacy of Single Pass Albumin Dialysis in Patients With Acute on Chronic Liver Failure
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Cirrhosis
Acute on Chronic Hepatic Failure
Hepatorenal Syndrome
Encephalopathy
Keywords: Albumin dialysis
Artificial liver support
Acute on chronic liver failure
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
Collaborators: name: Laboratoire français de Fractionnement et de Biotechnologies
name: Institut National de la Santé Et de la Recherche Médicale, France
First posted: 2008-10-01
Enrollment: 11
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of this study is to determine whether a simplified device of albumin dialysis also has beneficial effects.

Detailed description: Albumin dialysis has beneficial effects in patients with acute on chronic liver failure. However, current devices are complex and costly. The aim of this study is to determine whether a simplified device of albumin dialysis also has beneficial effects.

Eligibility criteria: Inclusion Criteria:

* Minimum age of 18 years
* Written consent after information of the patient or, in case of inability, by a parent or a close if he is present.
* Patient having a cirrhosis researched by previous exams (liver biopsy) or, in the absence of previous diagnosis, diagnosed in view of the results of clinical, biological and morphological data, whatever the origin of the cirrhosis (virus of hepatitis B, virus of hepatitis C, extreme consumption of alcohol or other reasons)

Exclusion Criteria:

* Participation to an other study in the 4 weeks before
* Active digestive bleeding, unchecked by the pharmacological treatments and the endoscopic techniques.

Primary outcomes:
measure: Effects on clinical and biochemical variables
timeFrame: 3 months follow-up
Secondary outcomes:
measure: Safety
timeFrame: 3 months
Other outcomes:
Locations:
city: Clichy
country: France
facility: Hôpital Beaujon
Study officials:
affiliation: Assistance Publique - Hôpitaux de Paris
name: François Durand, Pr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05245149: Image Quality and Radiation Dose Associated With Cardiac Scans in Modern CT Scanners
Official title: Prospective Observational Study of Image Quality and Radiation Dose Associated With Cardiac Scans in Modern CT Scanners
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Coronary Artery Disease
Keywords: Spectral CT
Multi-Energy CT
Photon Counting Detector CT
PCD-CT
Lead sponsor: University Hospital Augsburg
Sponsor class: OTHER
First posted: 2022-02-17
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients who are at least 18 years of age with a clincially indication for a coronary CTA scan. Indication ('justified indication' according to German/European radiation protection law) must be confirmed by a board-certified radiologist.

Brief summary: The main objective of this study is to evaluate the dose efficiency of coronary CT angiography (CTA) using a photon counting detector CT (PCD-CT) with the dose efficiency of coronary CT angiography of prior CT generations. 100 patients with a clinical indication for coronary CT angiography will be prospectively enrolled and undergo coronary CTA on a PCD-CT. For comparison, a matched retrospective cohort of 100 patients will be created who had undergone on a prior scanner generation (retrospective cohort).


Eligibility criteria: Inclusion Criteria:

* indication for coronary CTA confirmed by board-certified radiologist ('justified indication' according to German/European radiation protection law) AND
* patient (is able to give informed consent and) has given informed consent.

Exclusion Criteria:

* contraindications to (iodine based) iv contrast material: known allergy to iodine-based iv contrast, acute or high-grade chronic kidney insufficiency with an estimated glomerular filtration rate \< 30 ml/min/1.73 m², latent or manifest hyperthyroidism
* known or suspected pregnancy
* lactating mothers

Primary outcomes:
measure: Intraluminal Enhancement of Coronary Arteries
timeFrame: 1 year
measure: Image Noise
timeFrame: 1 year
measure: Overall subjective image quality
timeFrame: 1 year
measure: Dose-Length Product (DLP)
timeFrame: 1 year
Secondary outcomes:
measure: Diagnostic Accuracy of Coronary Artery Stenosis Assessment in Comparison with invasive catheter angiography
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
affiliation: University Hospital Augsburg
name: Florian Schwarz, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03282136: Incretin and CRTd.
Official title: Incretin Treatment Effect in Type 2 Diabetes Mellitus Patients Affected by Heart Failure With Depressed Ejection Fraction, and Treated by Cardiac Resynchronization Therapy With a Defibrillator.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Type 2 Diabetes Mellitus
Heart Failure
Lead sponsor: University of Campania Luigi Vanvitelli
Sponsor class: OTHER
First posted: 2017-09-13
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Incretin therapy is a treatment for type 2 diabetes (T2DM) affected by heart failure (HF). In this study the investigators will recruit T2DM patients affected by HF with depressed ejection fraction and treated by Cardiac resynchronization therapy (CRT). These patients will randomly be treated by incretin v/s conventional hypoglicemic drugs. In this patients investigators will report at follow up CRT-d responders rate, mortality, and hospital admission for HF worsening. Incretin may reduce hospital admissions for HF in T2DM v/s conventional hypoglicemic drugs.


Eligibility criteria: Inclusion Criteria:

* aged more than 18 years, with clinical hystory of T2DM non insulin dependent, and diagnosed failing heart with depressed ejection fraction; CRTd recipients.

Exclusion Criteria:

* T2DM in insuline therapy; renal impairment, chronic inflammatory and systemic diseases; neoplastic diseases.

Primary outcomes:
measure: all cause mortality, and cardiac cause mortality.
timeFrame: 12 months
Secondary outcomes:
measure: hospital admissions for HF
timeFrame: 12 months
Other outcomes:
Locations:
city: Naples
country: Italy
facility: Raffaele Marfella
Study officials:
References:
citation: Sardu C, Paolisso P, Sacra C, Santamaria M, de Lucia C, Ruocco A, Mauro C, Paolisso G, Rizzo MR, Barbieri M, Marfella R. Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate. Cardiovasc Diabetol. 2018 Oct 22;17(1):137. doi: 10.1186/s12933-018-0778-9.
Clinical trial NCT00102349: HIV and HCV Intervention In Drug Treatment Settings - 1
Official title: HIV and HCV Intervention in Drug Treatment Settings
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Behavior Therapy
Keywords: behavioral intervention
Lead sponsor: National Institute on Drug Abuse (NIDA)
Sponsor class: NIH
Collaborators: name: Oregon Health and Science University
First posted: 2005-01-28
Enrollment: 706
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to test two strategies to reduce the risk of contracting Human Immunodeficiency Virus (HIV) or Hepatitis C Virus (HCV) by reducing risk behaviors in patients undergoing drug detoxification.


Eligibility criteria: Volunteers will be IV drug users already enrolled in drug detoxification treatment.

Primary outcomes:
measure: HIV/HCV injection risk behaviors
Secondary outcomes:
Other outcomes:
Locations:
city: Denver
country: United States
facility: Denver Health & Hosp Authority
state: Colorado
city: Greeley
country: United States
facility: Island Grove RTC
state: Colorado
city: Fall River
country: United States
facility: SSTAR (Stanley St. Treatment & Resources, Inc)
state: Massachusetts
city: Kalamazoo
country: United States
facility: James Gilmore Jr. Treatment Center
state: Michigan
city: Eugene
country: United States
facility: Willamette Family Treatment Services
state: Oregon
city: North Kingstown
country: United States
facility: SSTAR of Rhode Island - North Kingstown
state: Rhode Island
city: Kent
country: United States
facility: Recovery Center King Co.-Kent Detox
state: Washington
city: Seattle
country: United States
facility: Recovery Center King Co.-Seattle Detox
state: Washington
Study officials:
affiliation: University of Colorado, Denver
name: Robert Booth, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01869049: The Alteration of Macrophage Function in the Spleen Tissues From Patients With Primary Immune Thrombocytopenia
Official title: A Study on the Alteration of Macrophage Function in the Spleen Tissue From Patients With Primary Immune Thrombocytopenia (ITP): a Multicenter, Perspective, Clinical Trial
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Immune Thrombocytopenia
Keywords: Immune Thrombocytopenia
macrophage
spleen tissue
Lead sponsor: Shandong University
Sponsor class: OTHER
First posted: 2013-06-05
Enrollment: 0
Sex: ALL
Minimum age (years): 15
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Chinese Adult with primary immune thrombocytopenia

Brief summary: This project was undertaken by Qilu Hospital of Shandong University and other well-known hospitals in China. In order to report the alteration on the macrophage function in the spleen tissue of primary immune thrombocytopenia (ITP).


Eligibility criteria: Inclusion Criteria:

* adult ITP patients whose platelet counts remain less than 10 x 10\^9/L
* patients whose platelet counts remain less than 30 x 10\^9/L and who continue to experience excessive bleeding after 4 to 6 weeks of appropriate medical treatment
* patients who have experienced a transient response to primary treatment and have platelet counts less than 30 x 10\^9/L after 3 months
* require continuous glucocorticoid therapy to maintain safe platelet counts
* Willing and able to sign written informed consent.

Exclusion Criteria:

* Received chemotherapy or anticoagulants or other drugs affecting the platelet counts within 3 months before the screening visit.
* Current HIV infection or hepatitis B virus or hepatitis C virus infections.
* Severe medical condition (lung, hepatic or renal disorder) other than chronic ITP. Unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure, uncontrolled hypertension or cardiac arrhythmia)
* Female patients who are pregnant.
* Have a known diagnosis of other autoimmune diseases, established in the medical history and laboratory findings with positive results for the determination of antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct Coombs test.
* Patients who are deemed unsuitable for the study by the investigator.

Primary outcomes:
measure: Evaluation of platelet response (Complete Response)
timeFrame: The time frame is up to 3 months per subject
measure: Evaluation of platelet response (R)
timeFrame: The time frame is up to 3 months per subject
measure: Evaluation of platelet response (No Response)
timeFrame: The time frame is up to 3 months per subject
Secondary outcomes:
measure: Macrophage Function
timeFrame: two weeks
Other outcomes:
Locations:
city: Jinan
country: China
facility: Qilu Hospital, Shandong University
state: Shandong
Study officials:
affiliation: Qilu Hospital, Shandong University
name: Jun Peng, dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06910449: Hemithoracic Arc Radiotherapy Post Pleural Decortication
Official title: Hemithoracic Volumetric Modulated Arc Radiotherapy as Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma Phase II Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Malignant Pleural Mesothelioma
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2025-04-04
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Malignant Pleural Mesothelioma is an aggressive and refractory disease , the most aggressive treatment plan offered to these patients include trimodalitiy approach with chemotherapy as the mainstay of treatment . the rationale of post operative Radiotherapy is to sterilize the post operative volume to reduce local failure meanwhile minimizing toxicities in this trial we are going to assess the safety and efficacy of Radiotherapy in Mesothelioma patients poat Pleural decortication

Detailed description: This study will include malignant Pleural Mesothelioma patients treated by trimodalitiy approach starting with neoadjuvant chemotherapy followed by surgery in the form of Pleural decortication then all patients will receive post operative hemithoracic radiation

Eligibility criteria: Inclusion Criteria:

* Evidence of metastatic disease.
* Underwent Pleural decortication.
* Able to provide informed consent.

Exclusion Criteria:

* Poor pulmonary function tests.
* Recurrent or palliative cases.
* Inability to attend full course of Radiotherapy or follow up visits.

Primary outcomes:
measure: Acute Radiation Toxicity
timeFrame: weekly assessment during radiation course and monthly follow up for the first 6 months
measure: late radiation toxicity
timeFrame: Bi-monthly fashion of minimum 6 months post radiation course
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: national Cancer Institute Cairo university
state: Fom Elkhalig
Study officials:
References: